Nurix Therapeutics Inc [NRIX] stock is trading at $21.92, up 1.81%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NRIX shares have gain 9.55% over the last week, with a monthly amount drifted -3.90%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Nurix Therapeutics Inc [NASDAQ: NRIX] stock has seen the most recent analyst activity on July 31, 2024, when Truist initiated its Buy rating and assigned the stock a price target of $36. On March 09, 2023, Barclays initiated with a Overweight rating and assigned a price target of $20 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $25 on February 28, 2023. Morgan Stanley initiated its recommendation with a Equal-Weight and recommended $11 as its price target on October 11, 2022. Wells Fargo upgraded its rating to Overweight for this stock on May 31, 2022, but kept the price target unchanged to $25. In a note dated February 10, 2022, Wells Fargo initiated an Equal Weight rating and provided a target price of $28 on this stock.
Nurix Therapeutics Inc [NRIX] stock has fluctuated between $4.22 and $24.38 over the past year. Currently, Wall Street analysts expect the stock to reach $27.43 within the next 12 months. Nurix Therapeutics Inc [NASDAQ: NRIX] shares were valued at $21.92 at the most recent close of the market. An investor can expect a potential return of 25.14% based on the average NRIX price forecast.
Analyzing the NRIX fundamentals
Nurix Therapeutics Inc [NASDAQ:NRIX] reported sales of 62.30M for the trailing twelve months, which represents a drop of -60.58%. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at -2.87%, Pretax Profit Margin comes in at -2.65%, and Net Profit Margin reading is -2.65%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -0.68 and Total Capital is -0.42. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.46 points at the first support level, and at 20.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.43, and for the 2nd resistance point, it is at 22.93.
Ratios To Look Out For
For context, Nurix Therapeutics Inc’s Current Ratio is 5.57. Also, the Quick Ratio is 5.57, while the Cash Ratio stands at 1.45. Considering the valuation of this stock, the price to sales ratio is 22.66, the price to book ratio is 3.81.
Transactions by insiders
Recent insider trading involved van Houte Hans, Chief Financial Officer, that happened on Aug 01 ’24 when 3477.0 shares were sold. Chief Legal Officer, Ring Christine completed a deal on Aug 01 ’24 to sell 5760.0 shares. Meanwhile, Officer JOHANNES VAN HOUTE bought 3477.0 shares on Aug 01 ’24.
